MGEN - Miragen Therapeutics Inc (Healthcare: Diagnostics & Research) Projected Earnings Date: 0000-02-29    (Delayed quote data   2025-10-21)
Last
 24.02		 Change
 ⇓ -0.07   (-0.29%)		 Volume
  782,377
Open
 24.65		 High
 24.65		 Low
 23.65
8EMA (Daily)
 22.98		 40EMA (Daily)
 20.62		 50EMA (Daily)
 20.16		 STO (Daily)
 87.912		 MACD Hist (Daily)
 0.267
8EMA (Weekly)
 21.138		 40EMA (Weekly)
 17.96		 50EMA (Weekly)
 17.80		 STO (Weekly)
 91.867		 MACD Hist (Weekly)
 0.505
Company Profile
Miragen Therapeutics Inc is a US-based clinical-stage biopharmaceutical company discovering and developing proprietary RNA (Ribonucleic acid)-targeted therapeutics. The company?s main product candidates, MRG-106, MRG-201, MRG-107, and MRG-110. MRG-106 and MRG-201 are currently in Phase 1 clinical trials. The company mainly focuses on developing such therapeutics which will target blood cancers, pathological fibrosis, neuro-inflammation, and revascularization.
optionchance optionchance
⇒ Home | Chart and Research | Education | About Us  

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Questions or Comments: support@optionchance.com
Copyright © 2025 OptionChance.com